OBJECTIVE: To assess the long term effectiveness of adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of relapse, on the basis of three successive randomised trials and one observational study conducted from June 1973 to December 1980. DESIGN: Cohort study. SETTING: Istituto Nazionale Tumori in Milan, Italy. MAIN OUTCOME MEASURES: Relapse free and overall survival, measured by univariate and multivariate analyses. RESULTS: After a median follow up of 28.5 years for the initial study, adjuvant CMF was found to reduce the relative risk of relapse significantly (hazard ratio 0.71, 95% confidence interval 0.56 to 0.91, P = 0.005) and death (0.79, 0.63 to 0.98, P = 0.04). Administration of CMF for 12 cycles does not seem superior to a shorter administration of six cycles. In the node negative and oestrogen receptor negative trial, intravenous CMF significantly reduced the relative risk of relapse of disease (0.65, 0.47 to 0.90, P = 0.009) and death (0.65, 0.47 to 0.92, P = 0.01) at a median follow up of 20 years. CONCLUSIONS: When delivered optimally, CMF benefits patients at risk of relapse of distant disease without evidence of detrimental effects in any of the examined subgroups.
OBJECTIVE: To assess the long term effectiveness of adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of relapse, on the basis of three successive randomised trials and one observational study conducted from June 1973 to December 1980. DESIGN: Cohort study. SETTING: Istituto Nazionale Tumori in Milan, Italy. MAIN OUTCOME MEASURES: Relapse free and overall survival, measured by univariate and multivariate analyses. RESULTS: After a median follow up of 28.5 years for the initial study, adjuvant CMF was found to reduce the relative risk of relapse significantly (hazard ratio 0.71, 95% confidence interval 0.56 to 0.91, P = 0.005) and death (0.79, 0.63 to 0.98, P = 0.04). Administration of CMF for 12 cycles does not seem superior to a shorter administration of six cycles. In the node negative and oestrogen receptor negative trial, intravenous CMF significantly reduced the relative risk of relapse of disease (0.65, 0.47 to 0.90, P = 0.009) and death (0.65, 0.47 to 0.92, P = 0.01) at a median follow up of 20 years. CONCLUSIONS: When delivered optimally, CMF benefits patients at risk of relapse of distant disease without evidence of detrimental effects in any of the examined subgroups.
Authors: P Eifel; J A Axelson; J Costa; J Crowley; W J Curran; A Deshler; S Fulton; C B Hendricks; M Kemeny; A B Kornblith; T A Louis; M Markman; R Mayer; D Roter Journal: J Natl Cancer Inst Date: 2001-07-04 Impact factor: 13.506
Authors: Raimund Jakesz; Hubert Hausmaninger; Ernst Kubista; Michael Gnant; Christian Menzel; Thomas Bauernhofer; Michael Seifert; Karin Haider; Brigitte Mlineritsch; Peter Steindorfer; Werner Kwasny; Michael Fridrik; Guenther Steger; Viktor Wette; Hellmut Samonigg Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: W Jonat; M Kaufmann; W Sauerbrei; R Blamey; J Cuzick; M Namer; I Fogelman; J C de Haes; A de Matteis; A Stewart; W Eiermann; I Szakolczai; M Palmer; M Schumacher; M Geberth; B Lisboa Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: S Ménard; P Valagussa; S Pilotti; L Gianni; E Biganzoli; P Boracchi; G Tomasic; P Casalini; E Marubini; M I Colnaghi; N Cascinelli; G Bonadonna Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: B Fisher; P Carbone; S G Economou; R Frelick; A Glass; H Lerner; C Redmond; M Zelen; P Band; D L Katrych; N Wolmark; E R Fisher Journal: N Engl J Med Date: 1975-01-16 Impact factor: 91.245
Authors: G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi Journal: N Engl J Med Date: 1976-02-19 Impact factor: 91.245
Authors: Christopher D Hart; Alessia Vignoli; Leonardo Tenori; Gemma Leonora Uy; Ta Van To; Clement Adebamowo; Syed Mozammel Hossain; Laura Biganzoli; Emanuela Risi; Richard R Love; Claudio Luchinat; Angelo Di Leo Journal: Clin Cancer Res Date: 2017-01-12 Impact factor: 12.531
Authors: Robert L Bretzel; Ralph Cameron; Marc Gustas; Maria A Garcia; Heather K Hoffman; Rosalind Malhotra; Karen Miller; Janine Prime; Anne Favret Journal: J Oncol Pract Date: 2009-11 Impact factor: 3.840
Authors: Thomas A Aloia; Giuseppe Zimmitti; Claudius Conrad; Vijaya Gottumukalla; Scott Kopetz; Jean-Nicolas Vauthey Journal: J Surg Oncol Date: 2014-05-21 Impact factor: 3.454